News | Radiation Therapy | October 17, 2018

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

After successful validation of Dolphin interoperability, online patient dose measurements during actual treatment delivery will enable verification of the correctness of each treatment fraction

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

October 17, 2018 — IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the Dolphin transmission detector for online monitoring of patient treatment.

With the health, security and safety of patients in focus, modern radiation therapy has become highly specialized, which has led to different complex treatment techniques being developed and used daily in patient cancer therapy. This in turn requires new and comprehensive quality assurance (QA) solutions that address the growing number of possible sources and impact of dose deviations, in particular for high-dose cases.

For online patient plan monitoring, IBA Dosimetry is set to release the Dolphin online solution with its Compass 3D verification software, and has therefore entered into an interoperability agreement with Varian.

The Dolphin online functionality enables the measurement of each fraction dose and the verification of the actual radiation dose delivered to patients. The ability to measure treatment accuracy fraction by fraction will provide the confidence and safety needed to deliver the highest quality of care to the patient.

Dolphin includes the following five checks for verification of the complete treatment chain:

  • Real measurement of the plan delivery. In contrast to solutions that purely recalculate the patient plan via log files, the Dolphin advanced high-resolution ionization chamber detector array enables real measurements of each fraction dose and detection of errors in treatment delivery, such as beam line defects, multileaf collimator (MLC) deviations, dose rate changes, flatness/symmetry drifts, gantry positioning errors, etc.;
  • Verification of the real patient plan where no surrogate QA plan is required;
  • Secondary dose calculation with treatment planning system (TPS)-class algorithm. Secondary verification of the TPS dose calculation enables detection of errors in the TPS algorithm, TPS performance or in the TPS export;
  • Machine constancy checks with myQA. In addition, Dolphin’s detector array is optimized to find deviations and trends in linear accelerator (LINAC) constancy for profiles, output and wedge factors; and
  • Independent verification of the treatment planning system. The independent beam model of Dolphin’s verification software enables detection of errors in the TPS configuration and performance, its beam model, commissioning, or the LINAC calibration
     

Dolphin is currently in clinical use around the world for advanced measurement-based pre-treatment patient QA.

For more information: www.iba-dosimetry.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve